Markets:

Overview

News

Currencies

International

Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

3.320 +0.120 (+3.75%)

Streaming Delayed Price Updated: 12:50 PM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >

SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds ↗

February 22, 2023

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its...

Via Benzinga

Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US ↗

February 15, 2023

Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications...

Via Benzinga

EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead ↗

February 01, 2023

(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

Via Benzinga

Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results ↗

January 31, 2023

Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained...

Via Benzinga

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗

January 25, 2023

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 25, 2023

It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!

Via InvestorPlace

EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When ↗

January 24, 2023

(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

Via Benzinga

EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains ↗

January 23, 2023

(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction

Via Benzinga

Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction ↗

January 20, 2023

(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to...

Via Benzinga

Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects ↗

January 19, 2023

Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.

Via Benzinga

Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results ↗

January 18, 2023

Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical...

Via Benzinga

This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials ↗

January 06, 2023

Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd.

Via Benzinga

What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways ↗

January 03, 2023

What a year for psychedelics!

Via Benzinga

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗

December 19, 2022

Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.

Via Benzinga

Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment ↗

December 19, 2022

Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for...

Via Benzinga

Why Third Harmonic Bio Shares Are Trading Lower By Over 78%? Here Are 40 Stocks Moving In Thursday's Mid-Day Session ↗

December 15, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) jumped 69.6% to $0.2604 after gaining 17% on Wednesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 15, 2022

It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

Via InvestorPlace

Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More ↗

November 29, 2022

LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon

Via Benzinga

Clearmind Gears Up For Clinical Trial To Test Drug That Treats Alcohol Addiction ↗

November 23, 2022

Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule.

Via Benzinga

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗

November 21, 2022

Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy

Via Benzinga

This Psychedelics Company Begins Trading On NASDAQ With $7.5M Offering Then Reverse Stock Split ↗

November 15, 2022

Psychedelics biotech firm Clearmind Medicine Inc.

Via Benzinga

Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected ↗

November 15, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.